Osteosarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Osteosarcoma, primarily found in children and adolescents, is the most frequently encountered primary bone malignancy. Despite its prevalence within this age group, it remains a rare condition, accounting for less than 1% of all cancer diagnoses in the United States. Unfortunately, comprehensive population-based data regarding its occurrence and outcomes are lacking. In young patients, osteosarcoma predominantly originates in the metaphyses of long bones, such as the distal femur (lower portion of the thighbone), proximal tibia (upper part of the shinbone), and proximal humerus (upper segment of the upper arm bone). While most cases arise during adolescence, there is a secondary peak of incidence among the elderly, occurring in their seventh and eighth decades. In older patients, these tumors are often considered secondary neoplasms stemming from the sarcomatous transformation of conditions like Paget's disease of bone or other benign bone lesions. Notably, in elderly patients, these tumors tend to occur more frequently in axial locations and areas previously exposed to radiation or with underlying bone abnormalities. The 5-year relative survival rate for osteosarcoma stands at 60%, but when diagnosed at a localized stage, it rises to 77%. Conversely, if the cancer has spread to nearby tissues or organs, the 5-year relative survival rate decreases to 65%.

·       Globally, the incidence of osteosarcoma is recorded at 3.4 cases per million individuals per year, with a higher prevalence in males than females.

 

Thelansis’s “Osteosarcoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Osteosarcoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Osteosarcoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Osteosarcoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Osteosarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Osteosarcoma, Osteosarcoma market outlook, Osteosarcoma competitive landscape, Osteosarcoma market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)